Asciminib hydrochloride is a Small Molecule owned by Novartis, and is involved in 25 clinical trials, of which 7 were completed, 16 are ongoing, and 2 are planned.
Asciminib hydrochloride is a selective allosteric inhibitor of BCR-ABL. The Bcr-Abl fusion protein tyrosine kinase is an abnormal enzyme produced by leukemia cells that contain the Philadelphia chromosome. The drug candidate binds to the Abl portion of the Bcr-Abl fusion protein at a location that is distinct from the ATP-binding domain. This binding results in the inhibition of Bcr-Abl-mediated proliferation and enhanced apoptosis of Philadelphia chromosome-positive (Ph+) hematological malignancies.
The revenue for Asciminib hydrochloride is expected to reach a total of $10.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Asciminib hydrochloride NPV Report.
Asciminib hydrochloride is originated and owned by Novartis.
Asciminib hydrochloride Overview
Asciminib hydrochloride (Scemblix) is an antineoplastic agent that targets the ABL myristoyl pocket (STAMP). It is formulated as tablets, film coated tablets for oral route of administration. Scemblix is indicated for the treatment of adult patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP), previously treated with two or more tyrosine kinase inhibitors (TKIs) and also for Ph+ CML in CP with the T315I mutation.
ABL-001 (asciminib hydrochloride) is under development for the treatment of chronic myelocytic leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. The drug candidate is administered orally. It targets BCR-ABL tyrosine kinase.
Novartis is a healthcare company that focuses on the discovery, development, manufacture and marketing of prescription and generic pharmaceutical products and eye care products. It provides drugs for the treatment of cancer, cardiovascular diseases, dermatological conditions, neurological disorders, ophthalmic and respiratory diseases, immune disorders, and infections, among others. The company offers generic medicines and biosimilars through Sandoz. Novartis conducts research in various disease areas through The Novartis Institutes for BioMedical Research (NIBR). The company operates through a network of subsidiaries and offices across the Americas, Europe, the Middle East, Africa, and Asia-Pacific. Novartis is headquartered in Basel, Switzerland.
The company reported revenues of (US Dollars) US$52,877 million for the fiscal year ended December 2021 (FY2021), an increase of 6% over FY2020. In FY2021, the company’s operating margin was 22.1%, compared to an operating margin of 20.3% in FY2020. In FY2021, the company recorded a net margin of 45.4%, compared to a net margin of 16.2% in FY2020. The company reported revenues of US$12,842 million for the third quarter ended September 2022, a decrease of 1.9% over the previous quarter.
Quick View – Asciminib hydrochloride
|Highest Development Stage|